Safety of alemtuzumab in a nationwide cohort of Finnish multiple sclerosis patients
Background Alemtuzumab is an effective disease-modifying therapy (DMT) for highly active multiple sclerosis (MS). However, safety concerns limit its use in clinical practice. Objectives To evaluate the safety of alemtuzumab in a nationwide cohort of Finnish MS patients. Methods In this retrospective...
Saved in:
Published in | Journal of neurology Vol. 269; no. 2; pp. 824 - 835 |
---|---|
Main Authors | , , , , , , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Berlin/Heidelberg
Springer Berlin Heidelberg
01.02.2022
Springer Nature B.V |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Be the first to leave a comment!